Post by Axxam

Cav3.2 cell line: A new milestone in our collaboration with B'SYS GmbH!   We're pleased to announce the successful completion of the first evaluation of a cell line expressing Cav3.2, one of the most actively investigated ion channel targets in pain and neuroscience drug discovery.   This achievement marks an important step forward: the cell line has now been qualified and is ready for high-throughput electrophysiology screening at Axxam.   We're looking forward to working with companies advancing therapies targeting this highly relevant ion channel.   Explore the attached PDF for all the details: https://lnkd.in/edQ97SbQ   #DrugDiscovery #Electrophysiology #HTS #IonChannels #PainResearch #Neuroscience #CNS